Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Mar 6;82(7):1364–1369. doi: 10.1054/bjoc.1999.1106

Non-steroidal anti-inflammatory drugs and bladder cancer prevention

J E Castelao 1, J-M Yuan 1, M Gago-Dominguez 1, M C Yu 1, R K Ross 1
PMCID: PMC2374480  PMID: 10755416

Abstract

Inclusion of phenacetin among ‘proven’ human carcinogens by the IARC in 1987, raised concerns about the carcinogenic potential of acetaminophen, its major metabolite. Acetaminophen has been implicated as a possible causal agent in the development of cancer of the renal pelvis. The bladder and renal pelvis, which derive from the same embryological structure, share the same transitional type of epithelium. Past studies have been inconclusive on the possible relationship among these analgesics and bladder cancer but no large, highly detailed study of this association has been conducted. A population-based case–control study conducted in Los Angeles, California, involved 1514 incident bladder cancer cases and an equal number of controls who were matched to the index cases by sex, date of birth (within 5 years) and race. Detailed information on medication use and prior medical conditions was collected through in-person interviews. Regular use of analgesics was not associated with an increased risk of bladder cancer in either men or women. In fact, compared with non- or irregular users, regular analgesic users were at a decreased risk of bladder cancer overall (odds ratio (OR) = 0.81, 95% confidence interval (CI) = 0.68–0.96). However, there were clear differences in both the direction and strength of the associations between the different formulation classes of analgesics and bladder cancer risk. Intake of phenacetin was positively related to bladder cancer risk in a dose-dependent manner while intake of its major metabolite in humans, acetaminophen, was unrelated to risk. Intake of all classes of NSAIDs, except pyrazolon derivatives, were negatively associated with bladder cancer risk, with suggestive evidence that the protective effect varies in strength by subcategories of formulation. Acetic acids seemed to exhibit the strongest protective effect, whereas aspirin/other salicylic acids and oxicam showed the weakest protection. © 2000 Cancer Research Campaign

Keywords: bladder cancer, analgesics, aspirin, acetaminophen, phenacetin, other NSAID drugs

Full Text

The Full Text of this article is available as a PDF (74.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angervall L., Bengtsson U., Zetterlund C. G., Zsigmond M. Renal pelvic carcinoma in a Swedish district with abuse of a phenacetin-containing drug. Br J Urol. 1969 Aug;41(4):401–405. doi: 10.1111/j.1464-410x.1969.tb09939.x. [DOI] [PubMed] [Google Scholar]
  2. Boring C. C., Squires T. S., Tong T., Montgomery S. Cancer statistics, 1994. CA Cancer J Clin. 1994 Jan-Feb;44(1):7–26. doi: 10.3322/canjclin.44.1.7. [DOI] [PubMed] [Google Scholar]
  3. Cohen S. M., Hasegawa R., Sakata T., Johansson S. L. Effect of aspirin on urinary bladder carcinogenesis initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in rats. Cancer Res. 1989 Jan 15;49(2):372–377. [PubMed] [Google Scholar]
  4. Denda A., Endoh T., Kitayama W., Tang Q., Noguchi O., Kobayashi Y., Akai H., Okajima E., Tsujiuchi T., Tsutsumi M. Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. Carcinogenesis. 1997 Oct;18(10):1921–1930. doi: 10.1093/carcin/18.10.1921. [DOI] [PubMed] [Google Scholar]
  5. Derby L. E., Jick H. Acetaminophen and renal and bladder cancer. Epidemiology. 1996 Jul;7(4):358–362. doi: 10.1097/00001648-199607000-00004. [DOI] [PubMed] [Google Scholar]
  6. DuBois R. N., Radhika A., Reddy B. S., Entingh A. J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology. 1996 Apr;110(4):1259–1262. doi: 10.1053/gast.1996.v110.pm8613017. [DOI] [PubMed] [Google Scholar]
  7. Flaks B., Flaks A., Shaw A. P. Induction by paracetamol of bladder and liver tumours in the rat. Effects on hepatocyte fine structure. Acta Pathol Microbiol Immunol Scand A. 1985 Nov;93(6):367–377. doi: 10.1111/j.1699-0463.1985.tb03964.x. [DOI] [PubMed] [Google Scholar]
  8. Fokkens W. Phenacetin abuse related to bladder cancer. Environ Res. 1979 Oct;20(1):192–198. doi: 10.1016/0013-9351(79)90097-5. [DOI] [PubMed] [Google Scholar]
  9. Gago-Dominguez M., Yuan J. M., Castelao J. E., Ross R. K., Yu M. C. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer. 1999 Oct;81(3):542–548. doi: 10.1038/sj.bjc.6690728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Giardiello F. M., Offerhaus G. J., DuBois R. N. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1071–1076. doi: 10.1016/0959-8049(95)00137-8. [DOI] [PubMed] [Google Scholar]
  11. Giovannucci E., Egan K. M., Hunter D. J., Stampfer M. J., Colditz G. A., Willett W. C., Speizer F. E. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995 Sep 7;333(10):609–614. doi: 10.1056/NEJM199509073331001. [DOI] [PubMed] [Google Scholar]
  12. Grubbs C. J., Juliana M. M., Eto I., Casebolt T., Whitaker L. M., Canfield G. J., Manczak M., Steele V. E., Kelloff G. J. Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors. Anticancer Res. 1993 Jan-Feb;13(1):33–36. [PubMed] [Google Scholar]
  13. Herschman H. R. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev. 1994 Dec;13(3-4):241–256. doi: 10.1007/BF00666095. [DOI] [PubMed] [Google Scholar]
  14. Hiraga K., Fujii T. Carcinogenicity testing of acetaminophen in F344 rats. Jpn J Cancer Res. 1985 Feb;76(2):79–85. [PubMed] [Google Scholar]
  15. Hultengren N., Lagergren C., Ljungqvist A. Carcinoma of the renal pelvis in renal papillary necrosis. Acta Chir Scand. 1965 Oct;130(4):314–320. [PubMed] [Google Scholar]
  16. Johansson S. L. Carcinogenicity of analgesics: long-term treatment of Sprague-Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetamidophen). Int J Cancer. 1981;27(4):521–529. doi: 10.1002/ijc.2910270416. [DOI] [PubMed] [Google Scholar]
  17. Johansson S., Wahlqvist L. Tumours of urinary bladder and ureter associated with abuse of phenacetin-containing analgesics. Acta Pathol Microbiol Scand A. 1977 Nov;85(6):768–774. doi: 10.1111/j.1699-0463.1977.tb03892.x. [DOI] [PubMed] [Google Scholar]
  18. Kargman S. L., O'Neill G. P., Vickers P. J., Evans J. F., Mancini J. A., Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 1995 Jun 15;55(12):2556–2559. [PubMed] [Google Scholar]
  19. Kari F., Bucher J., Haseman J., Eustis S., Huff J. Long-term exposure to the anti-inflammatory agent phenylbutazone induces kidney tumors in rats and liver tumors in mice. Jpn J Cancer Res. 1995 Mar;86(3):252–263. doi: 10.1111/j.1349-7006.1995.tb03048.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kelloff G. J., Boone C. W., Crowell J. A., Steele V. E., Lubet R., Sigman C. C. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):85–98. [PubMed] [Google Scholar]
  21. Klän R., Knispel H. H., Meier T. Acetylsalicylic acid inhibition of n-butyl-(4-hydroxybutyl)nitrosamine-induced bladder carcinogenesis in rats. J Cancer Res Clin Oncol. 1993;119(8):482–485. doi: 10.1007/BF01215929. [DOI] [PubMed] [Google Scholar]
  22. Kokmen E., Beard C. M., O'Brien P. C., Offord K. P., Kurland L. T. Is the incidence of dementing illness changing? A 25-year time trend study in Rochester, Minnesota (1960-1984) Neurology. 1993 Oct;43(10):1887–1892. doi: 10.1212/wnl.43.10.1887. [DOI] [PubMed] [Google Scholar]
  23. Kune G. A., Kune S., Watson L. F. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988 Aug 1;48(15):4399–4404. [PubMed] [Google Scholar]
  24. Liu X. H., Rose D. P. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996 Nov 15;56(22):5125–5127. [PubMed] [Google Scholar]
  25. Lupulescu A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids. 1996 Feb;54(2):83–94. doi: 10.1016/s0952-3278(96)90064-2. [DOI] [PubMed] [Google Scholar]
  26. Marnett L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 1992 Oct 15;52(20):5575–5589. [PubMed] [Google Scholar]
  27. McCredie M., Ford J. M., Taylor J. S., Stewart J. H. Analgesics and cancer of the renal pelvis in New South Wales. Cancer. 1982 Jun 15;49(12):2617–2625. doi: 10.1002/1097-0142(19820615)49:12<2617::aid-cncr2820491235>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  28. McCredie M., Stewart J. H. Does paracetamol cause urothelial cancer or renal papillary necrosis? Nephron. 1988;49(4):296–300. doi: 10.1159/000185079. [DOI] [PubMed] [Google Scholar]
  29. McCredie M., Stewart J. H., Ford J. M., MacLennan R. A. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. Br J Urol. 1983 Apr;55(2):220–224. doi: 10.1111/j.1464-410x.1983.tb06561.x. [DOI] [PubMed] [Google Scholar]
  30. McGeer P. L., Schulzer M., McGeer E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996 Aug;47(2):425–432. doi: 10.1212/wnl.47.2.425. [DOI] [PubMed] [Google Scholar]
  31. Moon R. C., Detrisac C. J., Thomas C. F., Kelloff G. J. Chemoprevention of experimental bladder cancer. J Cell Biochem Suppl. 1992;16I:134–138. doi: 10.1002/jcb.240501326. [DOI] [PubMed] [Google Scholar]
  32. Moon R. C., Kelloff G. J., Detrisac C. J., Steele V. E., Thomas C. F., Sigman C. C. Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis. 1993 Jul;14(7):1487–1489. doi: 10.1093/carcin/14.7.1487. [DOI] [PubMed] [Google Scholar]
  33. Murai T., Mori S., Machino S., Hosono M., Takeuchi Y., Ohara T., Makino S., Takeda R., Hayashi Y., Iwata H. Induction of renal pelvic carcinoma by phenacetin in hydronephrosis-bearing rats of the SD/cShi strain. Cancer Res. 1993 Sep 15;53(18):4218–4223. [PubMed] [Google Scholar]
  34. Murasaki G., Zenser T. V., Davis B. B., Cohen S. M. Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide-induced bladder carcinogenesis and enhancement of forestomach carcinogenesis. Carcinogenesis. 1984 Jan;5(1):53–55. doi: 10.1093/carcin/5.1.53. [DOI] [PubMed] [Google Scholar]
  35. Müller-Decker K., Scholz K., Marks F., Fürstenberger G. Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis. Mol Carcinog. 1995 Jan;12(1):31–41. doi: 10.1002/mc.2940120106. [DOI] [PubMed] [Google Scholar]
  36. O'Neill G. P., Mancini J. A., Kargman S., Yergey J., Kwan M. Y., Falgueyret J. P., Abramovitz M., Kennedy B. P., Ouellet M., Cromlish W. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol. 1994 Feb;45(2):245–254. [PubMed] [Google Scholar]
  37. Okajima E., Denda A., Ozono S., Takahama M., Akai H., Sasaki Y., Kitayama W., Wakabayashi K., Konishi Y. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res. 1998 Jul 15;58(14):3028–3031. [PubMed] [Google Scholar]
  38. Piper J. M., Tonascia J., Matanoski G. M. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med. 1985 Aug 1;313(5):292–295. doi: 10.1056/NEJM198508013130504. [DOI] [PubMed] [Google Scholar]
  39. Rao K. V., Detrisac C. J., Steele V. E., Hawk E. T., Kelloff G. J., McCormick D. L. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis. 1996 Jul;17(7):1435–1438. doi: 10.1093/carcin/17.7.1435. [DOI] [PubMed] [Google Scholar]
  40. Ristimäki A., Honkanen N., Jänkälä H., Sipponen P., Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997 Apr 1;57(7):1276–1280. [PubMed] [Google Scholar]
  41. Shibata M. A., Hasegawa R., Shirai T., Takesada Y., Fukushima S. Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model. Int J Cancer. 1993 Dec 2;55(6):1011–1017. doi: 10.1002/ijc.2910550622. [DOI] [PubMed] [Google Scholar]
  42. Thun M. J., Namboodiri M. M., Calle E. E., Flanders W. D., Heath C. W., Jr Aspirin use and risk of fatal cancer. Cancer Res. 1993 Mar 15;53(6):1322–1327. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES